Find drug development pipeline and deal Updates information

Lead Product(s): Tapentadol

Therapeutic Area: Neurology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Collegium Pharmaceutical

Deal Size: $375.0 million Upfront Cash: $375.0 million

Deal Type: Agreement February 06, 2020

Details:

Assertio Therapeutics has entered into a definitive agreement with Collegium Pharmaceutical, Inc. under which Collegium will acquire the NUCYNTA® franchise of products from the Company.